Form 4: Replimune Group Chief Commercial Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Replimune Group's Chief Commercial Officer, Christopher Sarchi, sold 5,207 shares of common stock to cover tax obligations related to the vesting of restricted stock units.
Summary
- Christopher Sarchi, Chief Commercial Officer of Replimune Group, Inc., sold 5,207 shares of common stock on November 18, 2024.
- The sale was executed at a price of $10.78 per share.
- This transaction was not a discretionary sale but rather a 'sell to cover' transaction to meet tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Sarchi directly owns 87,045 shares of Replimune Group common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance or outlook.
Industry Context
This is a routine transaction related to executive compensation and tax obligations, which is common in publicly traded companies. It does not indicate any change in the company's outlook or performance.
Comparison to Industry Standards
- Sales of shares to cover tax obligations upon vesting of restricted stock units are a standard practice among executives in publicly traded companies.
- The volume of shares sold is relatively small compared to the total outstanding shares of Replimune Group, and is not unusual for this type of transaction.
- Similar transactions are regularly reported by executives at comparable biotech companies, such as BioNTech, Moderna, and Regeneron, as part of their compensation packages.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
- The sale does not indicate any change in the company's performance or outlook.
Key Dates
| Date | Description |
|---|---|
| 11/18/2024 | Date of the stock sale transaction. |
| 11/20/2024 | Date the Form 4 was signed. |
Keywords
Replimune Group, insider trading, Form 4, stock sale, restricted stock units, tax obligations, Christopher Sarchi, Chief Commercial Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.